Latest / Conversations in Lung Cancer Research
Access to New Medicines: Which Surrogate Endpoints Matter
Do we need to evolve the bar on evidence required for drug reimbursement? The gold standard endpoint for assessing the benefit of anti-cancer drugs has been overall survival (OS) however, more recently, there has been a trend toward using surrogate clinical trial endpoints such as progression free survival (PFS) and event-free survival (EFS). As treatments improve and patients are living longer, using OS as a primary endpoint can mean a longer time until a result is obtained. In this podcast, Dr Rebecca Tay, Medical Oncologist at Royal Hobart Hospital and ICON, discusses the critical role of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.